search
Back to results

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (REVISE)

Primary Purpose

Gastrointestinal Hemorrhage (Clinically Important, Upper)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo (0.9% saline)
Pantoprazole
Sponsored by
McMaster University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Gastrointestinal Hemorrhage (Clinically Important, Upper)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or more.
  2. Receiving invasive mechanical ventilation in an ICU and in the opinion of the treating ICU physician mechanical ventilation will not be discontinued before the end of the day after tomorrow.

Exclusion Criteria:

  1. The treating clinician considers either Pantoprazole or placebo are indicated or contraindicated for this patient.
  2. Pantoprazole contraindicated for patient due to local product information;

    Australia/New Zealand;

    • being treated with HIV protease inhibitors atazanavir or nelfinavir
    • being treated with high dose methotrexate (i.e., greater than 300 mg as part of a chemotherapy regimen).
    • documented cirrhosis or severe liver disease (for example as indicated by an INR greater than 5.0 due to underlying liver disease).

    Canada;

    - being treated with rilpivirine or atazanavir

  3. Patients in whom a PPI or histamine 2 receptor antagonist (H2RA) is indicated due to active bleeding or increased bleeding risk, defined as patients with acute GI bleeding, severe oesophagitis or peptic ulcer disease within the previous 8 weeks, Zollinger Ellison syndrome, Barrett's oesophagus or any previous admission to hospital because of upper GI bleeding (patients receiving PPIs for mild dyspepsia or mild gastroesophageal reflux disease or an uncertain indication are not excluded).
  4. Received invasive mechanical ventilation during this ICU admission for 72 hours or more.
  5. Patients who have received more than 24 hours treatment (i.e., more than one daily dose equivalent) with a PPI or H2RA during this ICU admission.
  6. Being treated with or need for dual anti-platelet therapy.
  7. Admitted for palliative care or the ICU physician is not committed to continuing life-sustaining therapies at the time of enrolment.
  8. Known or suspected pregnancy.
  9. Physician, patient, or substitute decision maker (SDM) declines.
  10. Previously enrolled in the REVISE trial
  11. Enrolled in another trial for which co-enrolment is not approved.

Sites / Locations

  • University of Nebraska - Nebraska Medical Center
  • Bankstown-Lidcombe Hospital
  • Blacktown Hospital
  • Sutherland Hospital
  • Gosford Hospital
  • Nepean Hospital
  • St George Hospital
  • Royal North Shore Hospital
  • Wollongong HospitalRecruiting
  • Royal Brisbane Womens Hospital
  • Ipswich HospitalRecruiting
  • Mater Hospital
  • Princess Alexandra HospitalRecruiting
  • Royal Adelaide HospitalRecruiting
  • Bendigo Health
  • Geelong University Hospital
  • Austin HospitalRecruiting
  • Alfred Hospital
  • Royal Melbourne HospitalRecruiting
  • Epworth Hospital
  • Felicio Rocho Foundation - Hospital Felício Rocho
  • Sociedade Hospitalar Angelina CaronRecruiting
  • Santa Casa de Misericordia de Votuporanga
  • Foothills HospitalRecruiting
  • Peter Lougheed HospitalRecruiting
  • University of Alberta HospitalRecruiting
  • Nanaimo Regional General HospitalRecruiting
  • Royal Columbian HospitalRecruiting
  • Vancouver General HospitalRecruiting
  • Vancouver Island Health AuthorityRecruiting
  • St. Boniface HospitalRecruiting
  • Health Science Center WinnipegRecruiting
  • Grace HospitalRecruiting
  • Saint John Regional HospitalRecruiting
  • QEII Health Sciences CentreRecruiting
  • William Osler Hospital, McKenzie Health, Brampton Civic HospitalRecruiting
  • Brantford General HospitalRecruiting
  • Cambridge Memorial HospitalRecruiting
  • St. Joseph's Healthcare HamiltonRecruiting
  • Hamilton Health Science Center - General HospitalRecruiting
  • Hamilton Health Science Center - Juravinski HospitalRecruiting
  • Kingston General HospitalRecruiting
  • Grand River HospitalRecruiting
  • St. Mary's HospitalRecruiting
  • London Health Science Center (LHSC) - University HospitalRecruiting
  • London Health Science Center (LHSC) - Victoria HospitalRecruiting
  • North York General HospitalRecruiting
  • Ottawa Health Research Institute - OHRI (General and Civic Hospital)Recruiting
  • Niagara Health Services - St. Catharine's HospitalRecruiting
  • Sunnybrook Health Science CenterRecruiting
  • Mount Sinai HospitalRecruiting
  • University Health Network - Toronto Western HospitalRecruiting
  • St. Joseph's Health Centre, TorontoRecruiting
  • St. Michael's HospitalRecruiting
  • Windsor Regional HospitalRecruiting
  • Centre de recherche de l'Hôtel-Dieu de LévisRecruiting
  • Hôpital Maisonneuve RosemontRecruiting
  • Center Hospital University Montreal (CHUM)Recruiting
  • Centre Universitaire de Santé McGill / McGill University Health CentreRecruiting
  • CIUSS du Nord de l'île de Montréal - Hôpital du Sacré-Cœur de MontréalRecruiting
  • McGill University Health Centre - Montreal General HospitalRecruiting
  • CHU de Québec-Université Laval - Hôpital Enfant-JésusRecruiting
  • Institut Universitaire de cardiologie et de pneumologie de Québec Laval, QuebecRecruiting
  • Centre Hospitalier Universitaire de SherbrookeRecruiting
  • Regina General HospitalRecruiting
  • AL-Amiri HospitalRecruiting
  • Maroof International Hospital
  • King Abdulaziz Medical CenterRecruiting
  • Guys & St. Thomas HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo (0.9% saline)

Stress Ulcer Prophylaxis (Pantoprazole)

Arm Description

Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)

pantoprazole 40mg powder for injection reconstituted with 0.9% saline

Outcomes

Primary Outcome Measures

Rate of clinically important gastro-intestinal bleeding
Clinically important GI bleeding requires the presence of overt GI bleeding which is defined as one of the following; Hematemesis Overt nasogastric bleeding Melena Hematochezia PLUS (in the absence of another cause), at least one of the following in the 24 hours following overt GI bleeding: Haemodynamic change defined as a spontaneous decrease in invasively monitored mean arterial pressure or non-invasive systolic or diastolic blood pressure of 20 mmHg or more or an orthostatic increase in pulse rate of 20 beats/minute and a decrease in systolic blood pressure of 10 mmHg, with or without vasopressor initiation, or increase Vasopressor initiation A decrease in haemoglobin of ≥ 20 g/l in a 24-hour period or less, Transfusion of ≥2 units of packed red blood cells within 24 hours of bleeding to maintain stable haemoglobin or haemodynamics, or Need for therapeutic intervention (e.g. angiography, surgery or endoscopic treatment of bleeding).
Primary Safety Outcome: 90 Day Mortality
Mortality status at day 90 post randomization

Secondary Outcome Measures

Rate of ventilator associated pneumonia (VAP) in ICU
Diagnostic criteria for VAP include: previous mechanical ventilation for at least 48 hours, a new, progressive or persistent radiographic infiltrate on chest X-ray (without other obvious cause) plus at least 2 of the following 4 features: fever or hypothermia (temperature >38 °C or <36 °C) relative leukopenia or leukocytosis (WBC<4.0 or >12 x 10^9/L) purulent sputum gas exchange deterioration
Rate of clostridium difficile associated infection
We will use clinical features (diarrhea, ileus, toxic megacolon) and either microbiological evidence of toxin producing Clostridium difficile or Pseudomembranous colitis on colonoscopy.
New initiation of treatment with renal replacement therapy in ICU
Rate of New initiation of treatment with renal replacement therapy in ICU
Rate of all-cause-in-hospital mortality
hospital mortality
Rate of patient important GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization
Patient important GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization

Full Information

First Posted
November 21, 2017
Last Updated
October 3, 2023
Sponsor
McMaster University
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
search

1. Study Identification

Unique Protocol Identification Number
NCT03374800
Brief Title
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial
Acronym
REVISE
Official Title
Re-EValuating the Inhibition of Stress Erosions: Prophylaxis Against Gastrointestinal Bleeding in the Critically Ill (The REVISE) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 9, 2018 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
McMaster University
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients who are critically ill in the in the Intensive Care Unit (ICU), especially those who need a breathing machine, can develop ulcers in the stomach that bleed. To prevent bleeding, many such patients around the world receive a drug called pantoprazole that decreases acid production. However, today, compared to decades ago, critically ill patients rarely develop gastrointestinal bleeding. This decrease is likely due to modern medicine, better resuscitation and earlier feeding. There may also be harms associated with pantoprazole and other drugs that reduce acid levels in the stomach including lung infections (pneumonia) and bowel infections (clostridium difficile). Studies in this area are old and of modest quality. Therefore, it is difficult to know whether pantoprazole does decrease stomach bleeding these days, or whether the possible harms of lung and bowel infections are actually more common and more serious problems. The goal of this international study is to determine if, in critically ill patients using breathing machines, the use of pantoprazole is effective in preventing bleeding from stomach ulcers or whether it causes more problems such as lung infection (pneumonia) and bowel infection (Clostridium difficile), or whether pantoprazole has no effect at all. Whether the harms are worth the benefits, and whether the benefits are worth the costs, will be determined by an economic analysis to inform patients, families, clinicians, and healthcare systems globally.
Detailed Description
Background: For 40 years, pharmacologic prevention of stress ulcer-related gastrointestinal (GI) bleeding with acid suppression has been the standard of care for mechanically ventilated ICU patients. Worldwide, proton pump inhibitors (PPIs) are more commonly used than histamine-2-receptor antagonists. Observational studies and the latest network meta-analysis suggest that PPIs increase the risk of ventilator-associated pneumonia (VAP) and Clostridioides difficile infection (CDI). However, a recent large randomized trial showed that pantoprazole had no impact on the primary outcome of 90-day mortality. The secondary outcome (a composite of pneumonia, gastrointestinal bleeding, CDI and acute myocardial ischemia) was not different between the groups. Although pantoprazole was associated with a significantly lower rate of GI bleeding, some bleeding events required no blood transfusion, endoscopy or other diagnostic or therapeutic interventions, calling into question whether these bleeds were truly patient-important. Further, patients with high illness severity on pantoprazole had a significant, unexplainable higher risk of death than those receiving placebo. REVISE Pilot Trial: We completed the 91-patient REVISE Pilot Trial in Canada, Australia and Saudi Arabia, demonstrating a high consent rate (77.8%); recruitment rate (2.6 patients/month/center); and protocol adherence (96.8%), thereby successfully establishing the feasibility of a larger REVISE Trial. Objectives of the REVISE Trial: To determine, among mechanically ventilated patients, the effect of pantoprazole versus placebo on the primary efficacy outcome of clinically important upper GI bleeding, and the primary safety outcome of 90-day mortality. Secondary outcomes are VAP, CDI, acute kidney injury, hospital mortality and patient-important GI bleeding. Tertiary outcomes are transfused packed red blood cells, serum creatinine, duration of mechanical ventilation, duration of ICU stay and duration of hospital stay. Methods: We will include 4,800 ICU patients >18 years old who have an anticipated duration of mechanical ventilation of ≥48 hours. Exclusion criteria are acute or recent GI bleeding, dual antiplatelet therapy, combined antiplatelet and anticoagulant therapy, hopeless prognosis or intent to withdraw advanced life support, and previous enrolment in this or a confounding trial. Patients will be randomized in a fixed 1:1 allocation, stratified by center and pre-ICU acid suppression ('start or no start' strata, and 'continue or discontinue' strata). Research Coordinators will obtain informed consent using a deferred or a priori consent model. Study Pharmacists will obtain concealed allocation from the REVISE website; all research team and clinical team members, patients and families will be blinded. Patients will receive pantoprazole 40 mg or identical placebo intravenously daily while in ICU up to 90 days or until: 1) successful discontinuation of mechanical ventilation for >48 hours; 2) development of clinically important GI bleeding, or 3) death in ICU. Analyses will be by intention-to-treat and per protocol. Collaborations: REVISE will be conducted in collaboration with the Canadian Critical Care Trials Group, the Australian and New Zealand Critical Care Trials Group, other consortia and interested investigators, under the auspices of the International Forum for Acute Care Trialists. Ethical Imperative: Many factors converge to underscore the ethical imperative for REVISE. Critical care has evolved, research standards have improved, epidemiology may have changed, the risk:benefit and cost:benefit ratios of prophylaxis may have shifted. Thus, stress ulcer prophylaxis may need to be REVISED. Relevance: Most mechanically ventilated patients around the world receive daily stress ulcer prophylaxis, although variation exists such that some centers do not use any. Many RCTs of stress ulcer prophylaxis were conducted 10-30 years ago, several are at moderate or high risk of bias, and cointerventions may not reflect current critical care. A recent large trial raised concerns about death associated with pantoprazole in the most severely ill patient subgroup. Although GI bleeding events were less frequent, they may not have been patient-important, and there were no other benefits observed. Consensus in the scientific and clinical community is that equipoise remains regarding whether routine use of pantoprazole should continue for stress ulcer prophylaxis during critical illness. The question is especially important for patients who are receiving acid suppression pre-ICU, those who are receiving enteral nutrition, and those at high risk of death. Today, infectious complications of PPIs have emerged as potentially more common and serious than upper GI bleeding. The number needed to prophylax to prevent 1 GI bleed and the cost per GI bleed averted may be very high; furthermore, the number needed to harm to cause 1 episode of VAP or CDI may be low. Recent practice guidelines are conflicting. Remaining doubts about the effectiveness and safety of PPIs urge re-examination of universal prophylaxis for possible de-adoption. Aligned with the 'Choosing Wisely' Campaign, REVISE and the companion economic evaluation (E-REVISE) will be incorporated into guidelines to inform global practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Hemorrhage (Clinically Important, Upper)

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
A prospective, international, multicentre, parallel group, concealed, blinded, randomized trial in critically ill mechanically ventilated adults
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
blinded study drug and placebo
Allocation
Randomized
Enrollment
4800 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo (0.9% saline)
Arm Type
Placebo Comparator
Arm Description
Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
Arm Title
Stress Ulcer Prophylaxis (Pantoprazole)
Arm Type
Active Comparator
Arm Description
pantoprazole 40mg powder for injection reconstituted with 0.9% saline
Intervention Type
Drug
Intervention Name(s)
Placebo (0.9% saline)
Other Intervention Name(s)
normal saline; NaCl 0.9%
Intervention Description
normal saline
Intervention Type
Drug
Intervention Name(s)
Pantoprazole
Other Intervention Name(s)
Protonix
Intervention Description
40 mg powder for injection reconstituted with 0.9% saline
Primary Outcome Measure Information:
Title
Rate of clinically important gastro-intestinal bleeding
Description
Clinically important GI bleeding requires the presence of overt GI bleeding which is defined as one of the following; Hematemesis Overt nasogastric bleeding Melena Hematochezia PLUS (in the absence of another cause), at least one of the following in the 24 hours following overt GI bleeding: Haemodynamic change defined as a spontaneous decrease in invasively monitored mean arterial pressure or non-invasive systolic or diastolic blood pressure of 20 mmHg or more or an orthostatic increase in pulse rate of 20 beats/minute and a decrease in systolic blood pressure of 10 mmHg, with or without vasopressor initiation, or increase Vasopressor initiation A decrease in haemoglobin of ≥ 20 g/l in a 24-hour period or less, Transfusion of ≥2 units of packed red blood cells within 24 hours of bleeding to maintain stable haemoglobin or haemodynamics, or Need for therapeutic intervention (e.g. angiography, surgery or endoscopic treatment of bleeding).
Time Frame
90 days (In ICU or resulting in ICU readmission, censored at 90 days after randomization)
Title
Primary Safety Outcome: 90 Day Mortality
Description
Mortality status at day 90 post randomization
Time Frame
90 days post randomization
Secondary Outcome Measure Information:
Title
Rate of ventilator associated pneumonia (VAP) in ICU
Description
Diagnostic criteria for VAP include: previous mechanical ventilation for at least 48 hours, a new, progressive or persistent radiographic infiltrate on chest X-ray (without other obvious cause) plus at least 2 of the following 4 features: fever or hypothermia (temperature >38 °C or <36 °C) relative leukopenia or leukocytosis (WBC<4.0 or >12 x 10^9/L) purulent sputum gas exchange deterioration
Time Frame
90 Days (while in ICU,censored at 90 days after randomization)
Title
Rate of clostridium difficile associated infection
Description
We will use clinical features (diarrhea, ileus, toxic megacolon) and either microbiological evidence of toxin producing Clostridium difficile or Pseudomembranous colitis on colonoscopy.
Time Frame
90 days (during the index hospital admission, censored at 90 days)
Title
New initiation of treatment with renal replacement therapy in ICU
Description
Rate of New initiation of treatment with renal replacement therapy in ICU
Time Frame
90 Days (In the ICU, censored at 90 days)
Title
Rate of all-cause-in-hospital mortality
Description
hospital mortality
Time Frame
While in hospital, censored at 90 days after randomization
Title
Rate of patient important GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization
Description
Patient important GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization
Time Frame
Censored at 90 days after randomization
Other Pre-specified Outcome Measures:
Title
Total units of red blood cells transfused in the ICU
Description
Total units of red blood cells transfused in the ICU
Time Frame
Censored at 90 days after randomisation
Title
Peak serum creatinine concentration in ICU
Description
Peak serum creatinine concentration in ICU
Time Frame
Censored at 90 days after randomisation
Title
Duration of mechanical ventilation (days)
Description
Duration of mechanical ventilation (days)
Time Frame
Censored at 90 days after randomisation
Title
ICU length of stay (days)
Description
ICU length of stay (days)
Time Frame
Censored at 90 days after randomisation
Title
Hospital length of stay (days)
Description
Hospital length of stay (days)
Time Frame
Censored at 90 days after randomisation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or more. Receiving invasive mechanical ventilation in an ICU and in the opinion of the treating ICU physician mechanical ventilation will not be discontinued before the end of the day after tomorrow. Exclusion Criteria: The treating clinician considers either Pantoprazole or placebo are indicated or contraindicated for this patient. Pantoprazole contraindicated for patient due to local product information; Australia/New Zealand; being treated with HIV protease inhibitors atazanavir or nelfinavir being treated with high dose methotrexate (i.e., greater than 300 mg as part of a chemotherapy regimen). documented cirrhosis or severe liver disease (for example as indicated by an INR greater than 5.0 due to underlying liver disease). Canada; being treated with rilpivirine or atazanavir patients who are hypersensitive to pantoprazole, substituted benzimidazoles, or to any ingredient in the formulation Patients in whom a PPI or histamine 2 receptor antagonist (H2RA) is indicated due to active bleeding or increased bleeding risk, defined as patients with acute GI bleeding, severe oesophagitis or peptic ulcer disease within the previous 8 weeks, Zollinger Ellison syndrome, Barrett's oesophagus or any previous admission to hospital because of upper GI bleeding (patients receiving PPIs for mild dyspepsia or mild gastroesophageal reflux disease or an uncertain indication are not excluded). Received invasive mechanical ventilation during this ICU admission for 72 hours or more. Patients who have received more than 24 hours treatment (i.e., more than one daily dose equivalent) with a PPI or H2RA during this ICU admission. Being treated with or need for dual anti-platelet therapy. Admitted for palliative care or the ICU physician is not committed to continuing life-sustaining therapies at the time of enrolment. Known or suspected pregnancy. Physician, patient, or substitute decision maker (SDM) declines. Previously enrolled in the REVISE trial Enrolled in another trial for which co-enrolment is not approved.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Deborah J Cook, MD
Phone
905-979-9805
Email
debcook@mcmaster.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Nicole Zytaruk, RN
Phone
905-522-1155
Ext
35325
Email
zytaruk@mcmaster.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah Cook, MD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Nebraska - Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
987400
Country
United States
Individual Site Status
Completed
Facility Name
Bankstown-Lidcombe Hospital
City
Bankstown
State/Province
New South Wales
ZIP/Postal Code
2200
Country
Australia
Individual Site Status
Completed
Facility Name
Blacktown Hospital
City
Blacktown
State/Province
New South Wales
ZIP/Postal Code
2148
Country
Australia
Individual Site Status
Completed
Facility Name
Sutherland Hospital
City
Caringbah
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Completed
Facility Name
Gosford Hospital
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Individual Site Status
Completed
Facility Name
Nepean Hospital
City
Kingswood
State/Province
New South Wales
ZIP/Postal Code
2747
Country
Australia
Individual Site Status
Completed
Facility Name
St George Hospital
City
Kogarah
State/Province
New South Wales
ZIP/Postal Code
2217
Country
Australia
Individual Site Status
Completed
Facility Name
Royal North Shore Hospital
City
Saint Leonards
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Completed
Facility Name
Wollongong Hospital
City
Wollongong
State/Province
New South Wales
ZIP/Postal Code
2500
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Macpartlin, MD
Email
Matthew.Macpartlin@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Matthew Macpartlin, MD
Facility Name
Royal Brisbane Womens Hospital
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Individual Site Status
Completed
Facility Name
Ipswich Hospital
City
Ipswich
State/Province
Queensland
ZIP/Postal Code
4305
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neeraj Bhandange, MD
Email
Neeraj.Bhadange@health.qld.gov.au
First Name & Middle Initial & Last Name & Degree
Neeraj Bhandange, MD
Facility Name
Mater Hospital
City
South Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Individual Site Status
Completed
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kyle White, MD
Email
Kyle.white@health.qld.gov.au
First Name & Middle Initial & Last Name & Degree
Kyle White, MD
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianne Chapman, MD
Email
Marianne.Chapman@sa.gov.au
First Name & Middle Initial & Last Name & Degree
Marianne Chapman, MD
Facility Name
Bendigo Health
City
Bendigo
State/Province
Victoria
ZIP/Postal Code
3550
Country
Australia
Individual Site Status
Completed
Facility Name
Geelong University Hospital
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
Individual Site Status
Completed
Facility Name
Austin Hospital
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rinaldo Bellomo, MD
Email
rinaldo.bellomo@austin.org.au
First Name & Middle Initial & Last Name & Degree
Rinaldo Bellomo, MD
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Individual Site Status
Completed
Facility Name
Royal Melbourne Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Deane, MD
Email
adam.deane@mh.org.au
First Name & Middle Initial & Last Name & Degree
Adam Deane, MD
Facility Name
Epworth Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3121
Country
Australia
Individual Site Status
Completed
Facility Name
Felicio Rocho Foundation - Hospital Felício Rocho
City
Belo Horizonte
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana Carolina Nazaré, MD
First Name & Middle Initial & Last Name & Degree
Ana Carolina Nazaré, MD
Facility Name
Sociedade Hospitalar Angelina Caron
City
Campina Grande Do Sul
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dalton Bertolim Precoma, MD
First Name & Middle Initial & Last Name & Degree
Dalton Bertolim Precoma, MD
Facility Name
Santa Casa de Misericordia de Votuporanga
City
Votuporanga
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mauro Esteves Hernandes, MD
First Name & Middle Initial & Last Name & Degree
Mauro Esteves Hernandes, MD
Facility Name
Foothills Hospital
City
Calgary
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tom Stelfox, MD
First Name & Middle Initial & Last Name & Degree
tstelfox@ucalgary.ca
First Name & Middle Initial & Last Name & Degree
Tom Stelfox, MD
Facility Name
Peter Lougheed Hospital
City
Calgary
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Nivan, MD
First Name & Middle Initial & Last Name & Degree
Daniel.Niven@albertahealthservices.ca
First Name & Middle Initial & Last Name & Degree
Daniel Nivan, MD
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oleska Rewa, MD
Phone
780-492-9951
Email
rewa@ualberta.ca
First Name & Middle Initial & Last Name & Degree
Madia Baig
Phone
780-492-9951
Email
Nadia.Baig@albertahealthservices.ca
First Name & Middle Initial & Last Name & Degree
Oleska Rewa, MD
Facility Name
Nanaimo Regional General Hospital
City
Nanaimo
State/Province
British Columbia
ZIP/Postal Code
V9S 2B7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Ovakim, MD
Phone
250-508-6594
Email
Daniel.Ovakim@viha.ca
First Name & Middle Initial & Last Name & Degree
Daniel Ovakim, MD
Facility Name
Royal Columbian Hospital
City
New Westminster
State/Province
British Columbia
ZIP/Postal Code
V3L 3W7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Reynolds, MD
Phone
(604) 520-4253
Email
sreynolds.md@gmail.com
First Name & Middle Initial & Last Name & Degree
Steven Reynolds, MD
Facility Name
Vancouver General Hospital
City
Vancouver
State/Province
British Columbia
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Henderson, MD
Phone
(604) 875-4111
Email
william.henderson@vch.ca
First Name & Middle Initial & Last Name & Degree
William Henderson, MD
Facility Name
Vancouver Island Health Authority
City
Victoria
State/Province
British Columbia
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Ovakim, MD
Email
Daniel.Ovakim@viha.ca
First Name & Middle Initial & Last Name & Degree
Fiona Auld, RN
First Name & Middle Initial & Last Name & Degree
Daniel Ovakim, MD
Facility Name
St. Boniface Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ryan Zarychanski, MD
Phone
204-2358-3223
Email
rzarychanski@cancercare.mb.ca
First Name & Middle Initial & Last Name & Degree
Maggie Wilson
Phone
204-2358-3223
Email
NMARTEN@sbgh.mb.ca
First Name & Middle Initial & Last Name & Degree
Ryan Zarychanski, MD
Facility Name
Health Science Center Winnipeg
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1R9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Vasquez-Grande, MD
Email
gloriavazquezgrande@gmail.com
First Name & Middle Initial & Last Name & Degree
Gloria Vasquez-Grande, MD
Facility Name
Grace Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3J 3M7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Vasquez-Grande, MD
Email
gloriavazquezgrande@gmail.com
First Name & Middle Initial & Last Name & Degree
Gloria Vasquez-Grande, MD
Facility Name
Saint John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark, MD
Phone
506.648.6608
Email
mtutschka@gmail.com
First Name & Middle Initial & Last Name & Degree
Mark Tutschka, MD
Facility Name
QEII Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Osama Loubani, MD
Phone
902-473-7157
Email
oloubani@dal.ca
First Name & Middle Initial & Last Name & Degree
Osama Loubani, MD
Facility Name
William Osler Hospital, McKenzie Health, Brampton Civic Hospital
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6R 3J7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastien Trop, MD
Phone
905-494-2120
Email
sebastien.trop@gmail.com
First Name & Middle Initial & Last Name & Degree
Sebastien Trop, MD
Facility Name
Brantford General Hospital
City
Brantford
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda Reeve, MD
First Name & Middle Initial & Last Name & Degree
William Dechert
First Name & Middle Initial & Last Name & Degree
Brenda Reeve, MD
Facility Name
Cambridge Memorial Hospital
City
Cambridge
State/Province
Ontario
ZIP/Postal Code
N1R 3G2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingrid Morgan, MD
Phone
(519) 621-2330
Email
imorgan@cmh.org
First Name & Middle Initial & Last Name & Degree
Ingrid Morgan, MD
Facility Name
St. Joseph's Healthcare Hamilton
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L9N 4A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deborah Cook, MD
Phone
905-979-9805
Email
debcook@mcmaster.ca
First Name & Middle Initial & Last Name & Degree
France Clarke, RT
Phone
905-522-1155
Ext
35325
Email
clarkef@mcmaster.ca
First Name & Middle Initial & Last Name & Degree
Deborah Cook, MD
Facility Name
Hamilton Health Science Center - General Hospital
City
Hamilton
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maureen Meade, MD
First Name & Middle Initial & Last Name & Degree
Maureen Meade, MD
Facility Name
Hamilton Health Science Center - Juravinski Hospital
City
Hamilton
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bram Rochwerg, MD
First Name & Middle Initial & Last Name & Degree
Tina Millen, RT
First Name & Middle Initial & Last Name & Degree
Bram Rochwerh, MD
Facility Name
Kingston General Hospital
City
Kingston
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Muscedere, MD
First Name & Middle Initial & Last Name & Degree
Miranda Hunt
First Name & Middle Initial & Last Name & Degree
John Muscedere, MD
Facility Name
Grand River Hospital
City
Kitchener
State/Province
Ontario
ZIP/Postal Code
N2G 1G3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Hosek, MD
Phone
(519) 588-0331
Email
paul.hosek@grhosp.on.ca
First Name & Middle Initial & Last Name & Degree
Atif Siddiqui
Phone
(519) 588-0331
Email
Atif.Siddiqui@grhosp.on.ca
First Name & Middle Initial & Last Name & Degree
Paul Hosek, MD
Facility Name
St. Mary's Hospital
City
Kitchener
State/Province
Ontario
ZIP/Postal Code
N2M 1B2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Kruisselbrink, MD
Email
jadine2013@gmail.com
First Name & Middle Initial & Last Name & Degree
Rebecca Kruisselbrink, MD
Facility Name
London Health Science Center (LHSC) - University Hospital
City
London
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tina Mele, MD
First Name & Middle Initial & Last Name & Degree
Tracy Bental
First Name & Middle Initial & Last Name & Degree
Tina Mele, MD
Facility Name
London Health Science Center (LHSC) - Victoria Hospital
City
London
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ian Ball, MD
First Name & Middle Initial & Last Name & Degree
Eileen Campbell, RN
First Name & Middle Initial & Last Name & Degree
Ian Ball, MD
Facility Name
North York General Hospital
City
North York
State/Province
Ontario
ZIP/Postal Code
M2K 1E1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Geagea, MD
Phone
(416) 756-6000
Email
Anna.Geagea@nygh.on.ca
First Name & Middle Initial & Last Name & Degree
Anna Geagea, MD
Facility Name
Ottawa Health Research Institute - OHRI (General and Civic Hospital)
City
Ottawa
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shane English, MD
First Name & Middle Initial & Last Name & Degree
Irene Watpool
First Name & Middle Initial & Last Name & Degree
Shane English, MD
Facility Name
Niagara Health Services - St. Catharine's Hospital
City
St. Catharines
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erick Duan, MD
First Name & Middle Initial & Last Name & Degree
Erick Duan, MD
Facility Name
Sunnybrook Health Science Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rob Fowler, MD
Phone
(416) 480-6100
Email
rob.fowler@sunnybrook.ca
First Name & Middle Initial & Last Name & Degree
Rob Fowler, MD
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Geeta Mehta, MD
Phone
(416) 586-4800
Ext
8445
Email
samehta@mtsinai.on.ca
First Name & Middle Initial & Last Name & Degree
Sumesh Shah
Phone
(416) 586-4800
Email
Sumesh.Shah@SinaiHealthSystem.ca
First Name & Middle Initial & Last Name & Degree
Geeta Mehta, MD
Facility Name
University Health Network - Toronto Western Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 2S8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeff Singh, MD
Phone
(416) 603-5800
Ext
6203
Email
Jeff.Singh@uhn.ca
First Name & Middle Initial & Last Name & Degree
Jeff Singh, MD
Facility Name
St. Joseph's Health Centre, Toronto
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6R 1B5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joanne Meyer, MD
Phone
(416) 530-6090
Email
"Joanne Meyer" <Joanne.Meyer@unityhealth.to>
First Name & Middle Initial & Last Name & Degree
Joanne Meyer, MD
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Marshall, MD
First Name & Middle Initial & Last Name & Degree
John Marshall, MD
Facility Name
Windsor Regional Hospital
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N8W 1L9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Rahman, MD
Phone
5193195982
Email
Adam.Rahman@sjhc.london.on.ca
First Name & Middle Initial & Last Name & Degree
Adam Rahman, MD
Facility Name
Centre de recherche de l'Hôtel-Dieu de Lévis
City
Lévis
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Archambalt, MD
First Name & Middle Initial & Last Name & Degree
Patrick Archambalt, MD
Facility Name
Hôpital Maisonneuve Rosemont
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Marquis, MD
Phone
514-252-3400
Ext
4679
Email
f.marquis@umontreal.ca
First Name & Middle Initial & Last Name & Degree
Danae Tassey
Phone
514-252-3400
Ext
4679
Email
danae.tassy.cemtl@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Francois Marquis, MD
Facility Name
Center Hospital University Montreal (CHUM)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 0A9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuel Charbonney, MD
Phone
514 890-8000
Email
emmanuel.charbonney@umontreal.ca
First Name & Middle Initial & Last Name & Degree
Dounia Boumahni
Phone
514 890-8000
Email
dounia.boumahni.chum@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Emmanuel Charbonney, MD
Facility Name
Centre Universitaire de Santé McGill / McGill University Health Centre
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arnold Kristof, MD
First Name & Middle Initial & Last Name & Degree
Josie Campisi, RN
First Name & Middle Initial & Last Name & Degree
Arnold Kristof, MD
Facility Name
CIUSS du Nord de l'île de Montréal - Hôpital du Sacré-Cœur de Montréal
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuel Charbonney, MD
First Name & Middle Initial & Last Name & Degree
Virginie Williams, PhD
First Name & Middle Initial & Last Name & Degree
Emmanuel Charbonney, MD
Facility Name
McGill University Health Centre - Montreal General Hospital
City
Montréal
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kosar Khwaja, MD
First Name & Middle Initial & Last Name & Degree
Kosar Khwaja, MD
Facility Name
CHU de Québec-Université Laval - Hôpital Enfant-Jésus
City
Quebec City
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Lauzier, MD
First Name & Middle Initial & Last Name & Degree
Marie-Claude Trembley, BSc
First Name & Middle Initial & Last Name & Degree
Francois Lauzier, MD
Facility Name
Institut Universitaire de cardiologie et de pneumologie de Québec Laval, Quebec
City
Quebec City
State/Province
Quebec
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Lellouche, MD
Phone
418-656-8711
Ext
3937
Email
francois.lellouche@criucpq.ulaval.ca
First Name & Middle Initial & Last Name & Degree
Patricia Lizotte
Phone
418-656-8711
Ext
3937
Email
patricia.lizotte@criucpq.ulaval.ca
Facility Name
Centre Hospitalier Universitaire de Sherbrooke
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francois Lamontagne, MD
Phone
1-819-346-1110
Email
francoislamontagne@me.com
First Name & Middle Initial & Last Name & Degree
Joannie Marchand
Phone
1-819-346-1110
Email
jmarchand.chus@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Francois Lamontagne, MD
Facility Name
Regina General Hospital
City
Regina
State/Province
Saskatchewan
ZIP/Postal Code
S4P 0W5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Sy, MD
Phone
778-991-3514
Email
ers728@usask.ca
First Name & Middle Initial & Last Name & Degree
Eric Sy, MD
Facility Name
AL-Amiri Hospital
City
Kuwait City
Country
Kuwait
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdulrahman Al-Fares, MD
Email
abdulrahman.alfares@gmail.com
First Name & Middle Initial & Last Name & Degree
Abdulrahman Al-Fares, MD
Facility Name
Maroof International Hospital
City
Islamabad
Country
Pakistan
Individual Site Status
Completed
Facility Name
King Abdulaziz Medical Center
City
Riyadh
ZIP/Postal Code
11426
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yaseen Arabi, MD
Phone
011-966-1-2520088
Ext
1725
Email
Arabi@NGHA.MED.SA
First Name & Middle Initial & Last Name & Degree
Felwa Bin Humaid
Phone
0118011111
Ext
18382
Email
prospect@ngha.med.sa
First Name & Middle Initial & Last Name & Degree
Yaseen Arabi, MD
Facility Name
Guys & St. Thomas Hospital
City
London
State/Province
New Westminster
ZIP/Postal Code
SE1 7EH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marlies Ostermann, MD
Phone
+44 20 7188 7188
Email
Marlies.Ostermann@gstt.nhs.uk
First Name & Middle Initial & Last Name & Degree
Gill Arbane
Phone
07395 283492
Email
Gill.Arbane@gstt.nhs.uk
First Name & Middle Initial & Last Name & Degree
Marlies Ostermann, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Following the publication of REVISE, the dataset will be used for secondary observational studies addressing additional hypothesis-driven questions (e.g., predictors of gastrointestinal bleeding). Access by REVISE investigators will follow a submitted rationale, analysis plan and approval by the Management Committee. Requests for access to the dataset by external investigators will be considered following a submitted rationale, analysis plan and approval by the Management Committee and research ethics boards as relevant. Requirements will be stipulated in a pre-specified data sharing agreement. Only de-identified data will be provided and will be transferred via a secure web portal.
IPD Sharing Time Frame
Anticipated availability 2025 for up to 15 years.
IPD Sharing Access Criteria
Following the publication of REVISE, the dataset will be used for secondary observational studies addressing additional hypothesis-driven questions (e.g., predictors of gastrointestinal bleeding). Access by REVISE investigators will follow a submitted rationale, analysis plan and approval by the Management Committee. Requests for access to the dataset by external investigators will be considered following a submitted rationale, analysis plan and approval by the Management Committee and research ethics boards as relevant. Requirements will be stipulated in a pre-specified data sharing agreement. Only de-identified data will be provided and will be transferred via a secure web portal.

Learn more about this trial

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

We'll reach out to this number within 24 hrs